Select a medication above to begin.
MenQuadfi
meningococcal polysaccharide tetanus toxoid conjugate vaccine (MenACWY-TT)
Adult Dosing .
Dosage forms: INJ
invasive meningococcal dz prevention
- [18-55 yo, patients w/ low infection risk]
- Dose: 0.5 mL IM x1; Info: for military recruits, college students living in residential housing not previously vaccinated at 16 yo or older, lab workers exposed to N. meningitidis, or travelers to hyperendemic or epidemic areas; give booster q5y if continued risk in lab workers and travelers; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
- [18-55 yo, patients w/ high infection risk]
- Dose: 0.5 mL IM x2 doses at least 2mo apart; Info: for patients w/ asplenia, HIV infection, persistent complement component deficiency, or patients on complement inhibitor tx; give booster q5y if continued risk; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
- [56 yo and older, patients w/ low infection risk (off-label)]
- Dose: 0.5 mL IM x1; Info: for lab workers exposed to N. meningitidis or travelers to hyperendemic or epidemic areas; give booster q5y if continued risk; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
- [56 yo and older, patients w/ high infection risk (off-label)]
- Dose: 0.5 mL IM x2 doses at least 2mo apart; Info: for patients w/ asplenia, HIV infection, persistent complement component deficiency, or patients on complement inhibitor tx; give booster q5y if continued risk; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
renal dosing
- [no adjustment]
- renal impairment: no adjustment
- HD/PD: no adjustment; no supplement
hepatic dosing
- [no adjustment]
Peds Dosing .
- Dosage forms: INJ
invasive meningococcal dz prevention
- [routine vaccination]
- Dose: 0.5 mL IM x1 at 11-12 yo, then 0.5 mL IM x1 at 16 yo; Info: if 1st dose given at 13-15 yo, give booster at 16-18 yo; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [non-routine vaccination, 2 mo at series start]
- Dose: 0.5 mL IM x1 at 2 mo, 4 mo, 6 mo, and 12 mo for 4 total doses; Info: for patients w/ asplenia, sickle cell dz, HIV infection, persistent complement component deficiency, on complement inhibitor tx, or travelers to hyperendemic or epidemic areas; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [non-routine vaccination, 3-6 mo at series start (off-label)]
- Dose: 0.5 mL IM x3 doses at least 8wk apart, then 0.5 mL IM x1 dose at 12 mo or older and at least 12wk after prior dose; Info: for patients w/ asplenia, sickle cell dz, HIV infection, persistent complement component deficiency, on complement inhibitor tx, or travelers to hyperendemic or epidemic areas; 3rd dose not needed if 2nd dose given after 7 mo; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [non-routine vaccination, 7-23 mo at series start]
- Dose: 0.5 mL IM x2 doses at least 3mo apart; Info: for patients w/ asplenia, sickle cell dz, HIV infection, persistent complement component deficiency, on complement inhibitor tx, or travelers to hyperendemic or epidemic areas; give 2nd dose when patient 1 yo and older; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [non-routine vaccination, 2-6 yo, patients w/ low infection risk]
- Dose: 0.5 mL IM x1; Info: for travelers to hyperendemic or epidemic areas; give booster 3y after last dose, then q5y if continued risk; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [non-routine vaccination, 2-6 yo, patients w/ high infection risk]
- Dose: 0.5 mL IM x2 doses at least 8wk apart; Info: for patients w/ persistent complement component deficiency, complement inhibitor tx, asplenia, sickle cell dz, or HIV infection; give booster 3y after last dose, then q5y if continued risk; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [non-routine vaccination, 7 yo and older, patients w/ low infection risk]
- Dose: 0.5 mL IM x1; Info: for military recruits, college students living in residential housing not previously vaccinated at 16 yo or older, or travelers to hyperendemic or epidemic areas; give booster q5y if continued risk; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [non-routine vaccination, 7 yo and older, patients w/ high infection risk]
- Dose: 0.5 mL IM x2 doses at least 8wk apart; Info: for patients w/ persistent complement component deficiency, complement inhibitor tx, asplenia, sickle cell dz, or HIV infection; give booster q5y if continued risk; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
renal dosing
- [no adjustment]
- renal impairment: no adjustment
- HD/PD: no adjustment; no supplement
hepatic dosing
- [no adjustment]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- hypersensitivity to tetanus toxoid
- caution: Guillain-Barre syndrome history
- caution: immunocompromised patients
- caution: illness, acute moderate-severe
Drug Interactions .
Overview
meningococcal vaccine
vaccine
- non-live vaccine
Avoid/Use Alternative
- interferon gamma 1b
Monitor/Modify Tx
- abatacept
- abemaciclib
- abrocitinib
- acalabrutinib
- adalimumab
- ado-trastuzumab emtansine
- afamitresgene autoleucel
- aldesleukin
- alemtuzumab
- anakinra
- anifrolumab
- anti-thymocyte globulin
- atezolizumab
- atidarsagene autotemcel
- avelumab
- avutometinib
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- baricitinib
- basiliximab
- belatacept
- belimumab
- belinostat
- belzutifan
- bendamustine
- betamethasone
- bimekizumab
- blinatumomab
- bortezomib
- brentuximab vedotin
- brexucabtagene autoleucel
- brodalumab
- budesonide
- budesonide rectal
- busulfan
- cabazitaxel
- canakinumab
- capecitabine
- capmatinib
- carboplatin
- carfilzomib
- carmustine
- cemiplimab
- certolizumab pegol
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- cladribine oral
- clofarabine
- copanlisib
- corticotropin
- cortisone
- cosibelimab
- cyclophosphamide
- cyclosporine
- cytarabine
- dactinomycin
- daratumumab
- dasatinib
- daunorubicin
- decitabine
- defactinib
- deflazacort
- delgocitinib topical
- deucravacitinib
- deuruxolitinib
- dexamethasone
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- dordaviprone
- dostarlimab
- doxorubicin
- dupilumab
- durvalumab
- duvelisib
- efgartigimod alfa
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- epirubicin
- eribulin
- etanercept
- etoposide
- etrasimod
- everolimus
- fam-trastuzumab deruxtecan
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- fluorouracil
- fruquintinib
- gemcitabine
- gemtuzumab ozogamicin
- glofitamab
- golimumab
- guselkumab
- hydrocortisone
- hydroxyurea
- ibritumomab tiuxetan
- ibrutinib
- idarubicin
- idecabtagene vicleucel
- idelalisib
- ifosfamide
- imatinib
- inebilizumab
- infliximab
- inotuzumab ozogamicin
- ipilimumab
- irinotecan
- isatuximab
- ixabepilone
- ixekizumab
- lebrikizumab
- leflunomide
- lenalidomide
- linvoseltamab
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- lurbinectedin
- lymphocyte immune globulin, anti-thymocyte globulin
- margetuximab
- melphalan
- mercaptopurine
- methotrexate
- methylprednisolone
- mirikizumab
- mitomycin
- mitoxantrone
- mogamulizumab
- momelotinib
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- natalizumab
- nelarabine
- nemolizumab
- nilotinib
- nipocalimab
- nivolumab
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- oxaliplatin
- ozanimod
- paclitaxel
- palbociclib
- panobinostat
- peginterferon alfa 2a
- pembrolizumab
- pentostatin
- pertuzumab
- pirtobrutinib
- pneumococcal vaccine
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- prednisolone
- prednisone
- procarbazine
- regorafenib
- retifanlimab
- rilonacept
- ripretinib
- risankizumab
- ritlecitinib
- rituximab
- romidepsin
- ropeginterferon alfa-2b
- rozanolixizumab
- ruxolitinib
- sarilumab
- satralizumab
- secukinumab
- selinexor
- siltuximab
- siponimod
- sirolimus
- sirolimus albumin-bound
- sirolimus topical
- spesolimab
- sunitinib
- sunvozertinib
- tacrolimus
- tafasitamab
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- temsirolimus
- teplizumab
- teriflunomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- tislelizumab
- tocilizumab
- tofacitinib
- topotecan
- toripalimab
- tralokinumab
- tremelimumab
- triamcinolone
- ublituximab
- upadacitinib
- ustekinumab
- vamorolone
- vandetanib
- vedolizumab
- venetoclax
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanidatamab
- zanubrutinib
- zenocutuzumab
- zongertinib
Adverse Reactions .
Serious Reactions
- hypersensitivity rxn
- anaphylaxis
- Guillain-Barre syndrome
Common Reactions
- injection site rxn
- myalgia
- malaise
- fatigue
- headache
- drowsiness (peds patients)
- irritability (peds patients)
- appetite decr. (peds patients)
- vomiting (peds patients)
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Look/Sound-Alike Drug Names
MenQuadfi confused with: Menactra
Pregnancy/Lactation .
Pregnancy
Clinical Summary
may use during pregnancy; no human data available; no known risk of fetal harm based on animal data at 1x recommended human dose
Pregnancy Registry and Reporting
enroll patients in MedQuadfi Pregnancy Registry at 1-800-822-2463; report any suspected fetal exposure to VAERS at 1-800-822-7967
Lactation
Clinical Summary
may use while breastfeeding; no human data available, though risk of infant harm not expected based on vaccine properties; no human data available to assess effects on milk production
Pharmacology .
Metabolism: other; CYP450: unknown
Excretion: other; Half-life: unknown
Subclass: Meningococcal Vaccines ; Routine Adult Vaccines ; Routine Pediatric Vaccines ; Travel Vaccines
Mechanism of Action
exact mechanism of action unknown; induces antibody formation
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.